炎性因子调控1型糖尿病血管内皮细胞功能的研究进展

摘要/Abstract

摘要： 炎性因子不仅广泛参与1型糖尿病(T1DM)生理病理进程,亦参与血管内皮屏障功能调控过程;多种炎性因子通过激活氧化应激或调节相关受体,影响胰岛素信号传导通路,导致胰岛β细胞的凋亡,以及血管内皮细胞功能障碍。本文综述了T1DM与炎性因子如白介素家族、肿瘤坏死因子-α(TNF-α)、γ干扰素(INF-γ)、转化生长因子β1(TGF-β1)、叉头转录因子p3(Foxp3)的关系,并对炎性因子凝集素样氧化低密度脂蛋白受体-1(LOX-1)、可溶性血管细胞黏附分子(sVCAM)和活化T细胞核因子(NFAT)调控1型糖尿病血管内皮功能研究进行了回顾,展望了细胞因子免疫治疗T1DM 调节血管内皮功能的可能性。

关键词: 1型糖尿病, 血管内皮细胞功能, 炎性因子, 免疫治疗

Abstract: Inflammatory factors are widely involved not only in the physiopathological process of type 1 diabetes mellitus (T1DM), but also in the regulation of vascular endothelial dysfunction. A variety of inflammatory factors affect the insulin signaling pathway through activation of oxidative stress or regulation of related receptors, leading to apoptosis of pancreatic β-cells and vascular endothelial dysfunction. This article reviews the relationship between type 1 diabetes and the inflammatory factors interleukin family, tumor necrosis factor-α, interferon-γ, transforming growth factor β1, and fork head transcription factor p3. Furthermore, the research results on inflammatory factors, soluble vascular cell adhesion molecule (sVCAM), and nuclear factor of activated T cells (NFAT) regulating type 1 diabetes complicated with vascular endothelial dysfunction are reviewed and the potential cytokine immunotherapy modulating vascular endothelial dysfunction is envisioned.

Key words: type 1 diabetes, vascular endothelial cell, inflammatory factors, immunotherapy

中图分类号:

R587.1

李倩, 刘纯华, 王晨怡, 谈娇娇, 马玉萍, 吕海宏. 炎性因子调控1型糖尿病血管内皮细胞功能的研究进展[J]. 基础医学与临床, 2021, 41(10): 1497-1501.

LI Qian, LIU Chun-hua, WANG Chen-yi, TAN Jiao-jiao, MA Yu-ping, LYU Hai-hong. Progress of study on inflammatory factors regulating function of vascular endothelial cells from type 1 diabetes mellitus[J]. Basic & Clinical Medicine, 2021, 41(10): 1497-1501.

参考文献

[1]Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ,2020,369,m997. doi: 10.1136/bmj.m997.
[2]Chalakova T, Yotov Y, Tzotchev K, et al. Type 1 diabetes mellitus-risk factor for cardiovascular disease morbidity and mortality[J]. Current Diabetes Revie,2020. doi: 10.2174/1573399816666200511004205.
[3]Association AD. Improving Care and Promoting Health in Populations [J]. Diabetes Care,2020,43(Suppl 1):S7-S13.
[4]Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, et al. Cellular death, reactive oxygen species (ROS) and diabetic complications[J]. Cell Death Dis, 2018, 9: 119. doi: 10.1038/s41419-017-0135-z.
[5]Mantovani A, Dinarello CA, Molgora M, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity[J]. Immunity, 2019, 50: 778-795.
[6]White PC, Adhikari S, Grishman EK, et al. A phase I study of anti-inflammatory therapy with rilonacept in adolescents and adults with type 1 diabetes mellitus[J]. Pediatr Diabetes, 2018, 19: 788-793.
[7]Marcovecchio ML, Wicker LS, Dunger DB, et al. Interleukin-2 therapy of autoimmunity in diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial[J]. Wellcome Open Res. doi: 10.12688/wellcomeopenres.15697.1.
[8]Rajendran S, Anquetil F, Quesada-Masachs E, et al. IL-6 is present in beta and alpha cells in human pancre-atic islets: Expression is reduced in subjects with type 1 diabetes[J]. Clin Immunol, 2020,211, 108320.doi: 10.1016/j.clim.2019.108320.
[9]Jörns A, Ishikawa D, Teraoku H, et al. Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or/and anti-IL-6 in the IDDM rat model of type 1 diabetes[J]. BMC Med, 2020, 18: 33. doi: 10.1186/s12916-020-1503-6.
[10]Jörns A, Arndt T, Yamada S, et al. Translation of cura-tive therapy concepts with T cell and cytokine antibody combinations for type 1 diabetes reversal in the IDDM rat[J]. J Mol Med, 2020, 98:1125-1137.
[11]Oikawa Y, Sakamoto K, Satomura A, et al. Significance of peripheral mononuclear cells producing interferon-γ in response to insulin B:9-23-related peptides in subtypes of type 1 diabetes[J]. Clin Immunol, 2019, 208:108260. doi: 10.1016/j.clim.2019.108260.
[12]Nekoua MP, Fachinan R, Fagninou A, et al. Does control of glycemia regulate immunological parameters in insulin-treated persons with type 1 diabetes?[J]. Diabetes Res Clin Pract,2019,157:107868.doi:org/10.1016/j.diabres.2019.107868.
[13]Gonnellad D. Type 1 diabetes and MIG[J]. Clin Ter, 2019, 170: e465-e471.
[14]Dhawan S, Dirice E, Kulkarin RN, et al. Inhibition of TGF-β signaling promotes human pancreatic β-cell replication[J]. Diabetes, 2016, 65: 1208-1218.
[15]Lee J, Mellado-Gil JM, Bahn YJ, et al. Protection from β-cell apoptosis by inhibition of TGF-β/Smad3 signaling[J]. Cell Death Dis, 2020, 11: 184.doi: 10.1038/s41419-020-2365-8.
[16]Scherm MG, Serr I, Zahm AM, et al. miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes[J]. Nat Commun,2019, 10: 5697.doi: 10.1038/s41467-019-13587-3.
[17]Desbois A, Cacoub P, Leroyer AS, et al. Immunomodulatory role of Interleukin-33 in large vessel vasculitis[J]. Sci Rep, 2020,10: 6405. doi: 10.1038/s41598-020-63042-3.
[18]Liang J, Yuan S, Wang X, et al. Attenuation of pristimerin on TNF-α-induced endothelial inflammation[J]. Int Immunopharmacol,2020,82: 106326. doi: 10.1016/j.intimp.2020.106326.
[19]Luo E, Wang D, Yan G, et al. The NF-κB/miR-425-5p/MCT4 axis: a novel insight into diabetes-induced endothelial dysfunction[J]. Mol Cell Endocrinol, 2020, 500:110641. doi: 10.1016/j.mce.2019.110641.
[20]Sáez JC, Contreras-Duarte S, Gómez GI, et al. Connexin 43 hemichannel activity promoted by pro-inflammatory cytokines and high glucose alters endothelial cell function[J]. Front Immunol,2018,9:1899.doi: 10.3389/fimmu.2018.01899.
[21]Heim TW, Xu X, Ren Y, et al. Requisite roles of LOX-1, JNK, and arginase in diabetes-induced endothelial vasodilator dysfunction of porcine coronary arterioles[J]. J Mol Cell Cardiol, 2019,131: 82-90.
[22]Ma S, Bai Z, Wu H, et al. The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB[J]. Eur J Pharmacol, 2019, 851: 186-193.
[23]Barreto Silva MI, Klein MRST, Cardoso ÉS, et al. Synergistic effect of inflammatory cytokines and body adiposity on Insulin resistance and endothelial markers in patients With stages 3-5 chronic kidney disease[J]. J Ren Nutr, 2020, 30: 36-45.
[24]Roy MS, Janal MN, Crosby J, et al. Markers of endothelial dysfunction and inflammation predict progres-sion of diabetic nephropathy in African Americans with type 1 diabetes[J]. Kidney Int, 2015, 87: 427-433.
[25]Blanco F, Heinonen SE, Gurzeler E, et al. In vivo inhibition of nuclear factor of activated T-cells leads to atherosclerotic plaque regression in IGF-Ⅱ/LDLRApoB mice[J]. Diab Vasc Dis Res, 2018,15, 302-313.
[26]Garcia-Vaz E, Mcneilly AD, Berglund LM, et al. Inhibition of nFAT signaling restores microvascular endothelial function in diabetic mice[J]. Diabetes, 2020, 69:424-435.